NMN vs NR: The Nicotinamide Problem (Why We Chose NMN)

You are choosing an NAD+ precursor for a longevity stack after 40, not shopping for a chemistry lecture. RevGenetics sells Advanced NMN 1000. We do not sell nicotinamide riboside (NR). This article explains the science behind that choice: the nicotinamide (NAM) problem in sirtuin biochemistry, what oral NR and NMN actually do in humans, and where honesty still requires an open question mark.

Educational only. Structure/function and mechanism context. Not medical advice. Not a claim to diagnose, treat, cure, or prevent disease.

Direct answer

• Pick NMN if you want an NMN-forward stack (especially with a sirtuin-oriented polyphenol like resveratrol), clinical-range servings, and lot-level public COAs.
• You might still use NR if a clinician already has you on a verified NR protocol you tolerate and can document.
• Blood NAD+: in a Nestle open-label head-to-head, oral NR and NMN looked comparable (~2x whole-blood NAD+). That is not a sirtuin-activity win for either side.
• Strongest counterevidence first: oral NR at 1 g/day did not raise muscle NAM in aged men (Elhassan 2019). Methyl clearance products rose. So we will not say "NR floods NAM."

One reason stack builders lean NMN when they also use resveratrol: NR salvage pathways are discussed in research as one place where nicotinamide (NAM) can rise in the NAD+ cycle, and high NAM is described in biochemical literature as a sirtuin product inhibitor (for example PMID 12297502, PMID 15780941). People pairing a sirtuin-oriented polyphenol like resveratrol often prefer an NMN-forward stack for that reason. That is stack-logic and mechanism context, not a clinical proof that oral NR downregulates human sirtuins, and not a claim that NMN protects or activates sirtuins. RevGenetics sells Advanced NMN 1000 and does not sell NR. Educational only. Not a disease claim. Not "NR destroys sirtuins."

What this does not mean

• Not "NR destroys sirtuins"
• Not "NR is unsafe"
• Not a disease claim or reverse-aging claim
• Not a human clinical head-to-head that NMN beats NR for sirtuin activity
• Not a claim that NMN avoids NAM entirely (NAD+ cycling can involve NAM for both precursors)
• Soft brand reason we focus on NMN for sirtuin-oriented stacks; not a smear of NR

The nicotinamide problem (mechanism, not a smear)

Sirtuins are NAD+-dependent deacetylases. When they run, they produce O-acetyl-ADP-ribose and nicotinamide (NAM). Bitterman and colleagues (2002) showed that physiological concentrations of NAM inhibit yeast Sir2 and human SIRT1 in vitro, with an IC50 below 50 micromolar under their assay conditions (PMID 12297502). Avalos, Bever, and Wolberger (2005) then showed structurally how free NAM binds a conserved pocket that participates in NAD+ binding and catalysis, promoting a base-exchange reaction at the expense of deacetylation (PMID 15780941).

That is product inhibition biochemistry. It is not the same sentence as "taking an NR capsule shuts down your sirtuins." Later kinetics also show NAM sensitivity can be substrate-dependent (PMID 33670751). Treat IC50 and any Cheng-Prusoff "Ki ~17 micromolar" arithmetic as in vitro illustration with assumptions, not a measured free NAM concentration in your muscle after breakfast.

Separately, oncology research has studied high-dose NAM (about 1 g/day) as a sirtuin inhibitor in a lung adenocarcinoma trial design (PMID 38593249). That is disease-context pharmacology. It is not a longevity dosing guide, and it is not a claim about dietary NR.

Strongest counterevidence: Elhassan 2019

Before any brand preference, read the human muscle data. Elhassan and colleagues gave aged men 1 g/day NR for 21 days in a placebo-controlled crossover trial (PMID 31412242; DOI 10.1016/j.celrep.2019.07.043).

• Muscle NAM stayed flat: 92.0 vs 86.5 pmol/mg (NR vs placebo; p=0.96).
• Muscle NAD+ did not meaningfully rise (210 vs 197 pmol/mg; p=0.22).
• Methylated NAM clearance products rose sharply (MeNAM about fivefold; Me-2-py and Me-4-py also up).
• Chronic blood NAM was not elevated in that design.

Translation for buyers: oral NR increased NAM clearance traffic more than it parked NAM in muscle. Any honest NMN-vs-NR article must lead with that. Converting 92 pmol/mg into "~92 micromolar" assumes tissue density and free vs bound pools; that conversion is order-of-magnitude arithmetic, not a free cytosolic measurement. We keep it in the technical notes, not as a scare line.

Pathway map (say it once)

Simplified salvage neighborhood:

• NR -> (NRK enzymes) -> NMN -> (NMNAT enzymes) -> NAD+ (PMID 15137942)
• NMN -> (NMNAT) -> NAD+

NMN sits one enzymatic step closer to NAD+ on that map. That is mechanism education. It does not prove higher tissue NAD+ for every person, dose, or product.

Transport is a separate question. Mouse work reported Slc12a8 as an NMN transporter (PMID 31131364). Mouse findings generate hypotheses. They are not a proven human intestinal transporter guarantee for every product or person.

Why NR routing still matters (PNP, BST1, gut) without saying "floods NAM"

NR can be cleaved to NAM by documented enzymes:

• PNP (purine nucleoside phosphorylase) is a major intracellular route that turns NR into Nam in mammalian cells; blocking PNP redirects NR toward NAD+ synthesis (PMID 36265580; DOI 10.1016/j.jbc.2022.102615).
• BST1 appears in oral/in vivo NR handling literature as a glycohydrolase/base-exchange enzyme that can hydrolyse NR toward NAM and connect amidated/deamidated paths (Nature Communications 2021; DOI 10.1038/s41467-021-27080-3).

Gut microbiota add another layer. Mouse work shows oral NR and NMN can both be heavily processed toward nicotinic acid (NA) via microbiota-linked routes (Science Advances 2025; DOI 10.1126/sciadv.adr1538; PMID 40117359). Cell Metabolism 2022 likewise maps host-microbiome NAD precursor cycling (DOI 10.1016/j.cmet.2022.11.004; PMID 36476934). So we will not claim a clean story where only NR meets the gut and NMN does not.

What we will say: if your stack already cares about NAM/sirtuin biochemistry (especially with resveratrol), the extra NR->NAM cleavage neighborhood is one educational reason many people stay NMN-forward. Preference and mechanism context. Not a clinical superiority trial.

Human blood NAD+: Nestle head-to-head (disclose open-label + industry)

A randomized, open-label, placebo-controlled study in 65 healthy adults compared Nam, NR (1000 mg/day), and NMN (1000 mg/day) for 14 days (Nature Metabolism; DOI 10.1038/s42255-025-01421-8; PMID 41540253; NCT05517122). NR and NMN each raised whole-blood NAD+ about twofold versus placebo (reported concentration differences about 49.4 micromolar for NR and 43.1 micromolar for NMN). They were comparable to each other. Chronic Nam did not raise baseline NAD+ the same way.

Disclosure: multiple authors are employees of Nestle Research / Nestle Health Science (and one Cryptobiotix affiliation). Open-label designs can bias behavior and interpretation. Read it as useful blood-NAD+ comparison, not as proof that either precursor wins for sirtuin activity, muscle NAD+, or healthy-aging outcomes.

Category reviews also note oral NR and NMN can increase circulating NAD+ while clinical benefits stay variable and context-dependent (PMID 42489969).

NMN vs NR comparison table

Topic	NMN	NR
Molecule	Nicotinamide mononucleotide	Nicotinamide riboside
Path to NAD+	Primarily NMNAT toward NAD+. Transport is a separate research topic (mouse Slc12a8 literature).	NRK converts NR to NMN, then NMNAT toward NAD+ (PMID 15137942).
NAM / sirtuin stack note	Often preferred for NMN-forward stacks that include resveratrol. Soft preference / stack logic, not a clinical guarantee.	NR salvage and NR->NAM cleavage routes (PNP/BST1 literature) are discussed where NAM can rise in the cycle. High NAM is a sirtuin product inhibitor in biochemical literature (PMID 12297502, PMID 15780941). Soft only. Elhassan shows muscle NAM can stay flat with oral NR.
Blood NAD+ head-to-head	Comparable to NR in Nestle open-label 14-day study (disclose industry authors).	Comparable to NMN in same study.
Muscle NAD+	Not established as reliably superior in a definitive human head-to-head for tissue NAD+.	Elhassan: muscle NAD+ not significantly up at 1 g/day in that design.
Human sirtuin activity head-to-head	No 2024-2026 human trial found that directly compared oral NMN vs NR on SIRT1-7 catalytic activity.
Quality checkpoints	HPLC identity/purity, heavy metals, batch-matched public COA, enteric release testing as dissolution data only.	Same quality bar. Brand name is not a substitute for paperwork.

Resveratrol stacking: what is known vs untested

Howitz et al. (2003) reported that resveratrol can lower the Michaelis constant of SIRT1 for acetylated substrate and for NAD+ in vitro (PMID 12939617). Hubbard et al. (2013) mapped a common allosteric mechanism for SIRT1-activating compounds involving Glu230 (PMID 23471411).

Stack builders often pair a NAD+ precursor with resveratrol for that reason. Honest limits:

• No study we verified measured a NAM x resveratrol interaction on human sirtuin activity after oral NMN vs NR (Belardi 2024, Elhassan 2019, and Katayoshi 2023 do not close that gap).
• No peer-reviewed protocol settles dosing order (NMN before / with / after resveratrol) for human sirtuin outcomes.
• Classic in vitro resveratrol concentrations (often discussed around high micromolar assay levels) are not the same as typical human plasma exposures after oral supplements. Do not treat a 100 micromolar dish as your bloodstream.

So the arithmetic some enthusiasts write (resveratrol lowers Km for NAD+; NAM competes at the NAD+ site; therefore prefer NMN) is a hypothesis. We use it as stack-logic, then we say the interaction is untested.

Product reality check (COA, enteric, dose context)

Advanced NMN 1000 is positioned for adults who want a clinical-range NMN serving with enteric capsules and public batch paperwork. Product-page facts as of this rewrite: 1000 mg per serving (2 capsules), 99.2% HPLC purity language, and USP 711 dissolution testing reporting 84.8% intestinal release versus 12.5% for standard gelatin capsules. That is release / dissolution data, not clinical proof this product out-absorbs all NR supplements. Confirm your lot on the public certificates page.

Educational study ranges only (discuss with a clinician): NMN oral trials summarized in a 2026 systematic review commonly used about 250 to 2000 mg/day (PMID 42514320). NR human work includes open-label PK and RCT intakes such as 1000 mg twice daily in specific designs (PMID 29211728, PMID 29992272).

Why RevGenetics believes NMN is the better choice for our catalog

Here is our honest close. We are not claiming a universal clinical crown.

1. Shorter salvage neighborhood for our stack logic. NMN sits at the NMNAT step. NR adds NRK and documented NR->NAM cleavage routes (PNP intracellular; BST1 oral literature). If you already care about NAM as a sirtuin product inhibitor in biochemical literature, that extra neighborhood is a reason we stay NMN-forward.
2. Resveratrol / sirtuin stack fit. Many of our customers stack with sirtuin-oriented polyphenols. Soft preference for NMN in that lane. The NAM x resveratrol interaction remains untested in humans. We say that out loud.
3. Purity and paperwork we control. We source and publish lot-level COAs for Advanced NMN 1000. Catalog focus beats selling every precursor on the shelf.
4. What the blood data do not settle. Nestle open-label work shows NR and NMN can look similar for whole-blood NAD+. Elhassan shows oral NR need not flood muscle NAM. Chini and colleagues (2021) still frame NAD strategy choice as unsettled and context-dependent (PMID 33930322). Our belief is brand + mechanism + stack fit, not "the trial that ends the debate."

If your clinician already has you on verified NR, stay with what you can document. If you are building an NMN-forward longevity stack after 40, review Advanced NMN 1000 and check the lot on certificates. Soft look. No urgency. No disease claims. No "cures aging."

Technical notes (for readers who want the fine print)

• Cheng-Prusoff Ki ~17 micromolar: illustrative if you take IC50 = 50 micromolar at 200 micromolar NAD+ and Km = 100 micromolar under a competitive model. Bitterman called inhibition noncompetitive; Avalos/Wolberger describe base exchange at a shared NAD-related pocket. Treat ~17 micromolar as teaching arithmetic, not a clinical threshold.
• pmol/mg to micromolar: assumes ~1 mg/microliter tissue density and ignores free vs bound pools. Weak for scare copy. Useful only as order-of-magnitude discussion.
• Plasma resveratrol: oral supplement plasma levels are generally far below classic high-micromolar in vitro assay conditions. Compartment matters.
• Dropped citation: Yuan 2020 is not used here (unreliable for this argument).
• No new sirtuin-activity head-to-head: as of 2026-09-23 CT search, we found no human oral NMN vs NR trial that directly measured SIRT1-7 catalytic activity.

Related reading: what NMN is, how to evaluate NMN quality, RevGenetics Certificates of Analysis, and the Advanced NMN line. Product option: Advanced NMN 1000.

FAQ

What is the difference between NMN and NR?

Both are NAD+ precursors. NR is typically converted to NMN via NRK enzymes, then toward NAD+. NMN sits closer to NAD+ on that map. Educational pathway context only.

Do NMN and NR both raise blood NAD+?

Often yes in published human work. A Nestle open-label head-to-head found NR and NMN comparably raised whole-blood NAD+ over 14 days (PMID 41540253; disclose industry authors). Clinical outcome benefits remain variable (PMID 42489969).

Does oral NR flood muscle with nicotinamide?

Not in Elhassan 2019: muscle NAM was flat while methyl clearance products rose (PMID 31412242). Do not use "floods NAM" language.

Is NAM a sirtuin inhibitor?

In biochemical literature, yes as a product inhibitor of Sir2/SIRT1-class enzymes (PMID 12297502, PMID 15780941). That is not the same as proving oral NR downregulates human sirtuins in vivo.

Why might someone stacking resveratrol prefer NMN over NR?

NR salvage pathways are discussed in research as one place where nicotinamide (NAM) can rise in the NAD+ cycle. High NAM is described in biochemical literature as a sirtuin product inhibitor. People pairing a sirtuin-oriented polyphenol like resveratrol often prefer an NMN-forward stack for that reason. Educational mechanism context only. Not a clinical superiority trial and not "NR destroys sirtuins."

Why doesn't RevGenetics sell NR?

We focus on an NMN-forward SKU (Advanced NMN 1000). For customers stacking with sirtuin-oriented compounds like resveratrol, the NAM / product-inhibition context around NR salvage is one educational reason we stay NMN-forward. Soft brand focus. Not a claim that NR is unsafe or ineffective.

Do NMN and NR affect sirtuins the same way?

They are neighboring NAD+ precursors with different salvage dynamics. NAM as a sirtuin product inhibitor is a biochemical literature point; how oral NR vs NMN changes human sirtuin activity in vivo is not settled as a universal clinical winner. Prefer NMN-forward when the stack is sirtuin-oriented is preference / brand stack logic, not a proven disease or performance outcome.

Is there a human head-to-head on sirtuin activity for NMN vs NR?

As of our 2026-09-23 research pass, we did not find one. Blood NAD+ comparisons exist; sirtuin catalytic activity head-to-heads do not (in the sources we verified).

Does NMN need to convert to NR before entering cells?

Not necessarily in all models. Mouse research identified Slc12a8 as an NMN transporter (PMID 31131364). Remember the mouse-model caveat.

What doses appear in human research?

Educational ranges only: NMN studies summarized in PMID 42514320 often used about 250 to 2000 mg/day. NR work includes open-label PK and RCT intakes such as 1000 mg twice daily in a specific design (PMID 29211728, PMID 29992272). Confirm any personal plan with a clinician.

How do I verify quality?

Confirm identity, HPLC purity, heavy metals, and a public batch COA that matches your lot. Vague "third-party tested" claims are weaker than readable certificates.

Open question: does stacking order of NMN and resveratrol matter?

We do not have a human trial that settles dosing order or proves a NAM x resveratrol interaction after oral NMN vs NR. Treat stack timing as personal experimentation under clinician guidance, not settled science.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Educational content only. Discuss supplements with a qualified healthcare professional, especially if you are pregnant, nursing, managing a medical condition, or taking medications.

About the Author
Anthony Loera
Founder & President, RevGenetics